Eva Angenete, professor of surgery at the Institute of Clinical Sciences, was invited as the first “visiting fellow” to a new research initiative in Leeds. She now hopes for new research partnerships in colorectal surgery with her British colleagues.
Angenete recently took part in a new research initiative led by professor David Jayne at the Leeds University and John Goligher Colorectal Unit at Leeds Teaching Hospitals NHS. The project aims to bring together international experts to advance research in colorectal surgery.
“It is a great honor to have been the first invited to this newly established event. It was incredibly inspiring to see how similarly they run their clinical work to ours, and we found so many areas of common ground,” says Eva Angenete.
Presented research from Gothenburg
During her visit, Angenete presented her group’s research on local recurrence in rectal cancer.
“I talked about the projects in our research group SSORG and about our translational research that we conduct in collaboration with professor Ulf Yrlid in immunology. I shared the work we are doing to improve patients’ experiences from diagnosis through successful survival following colorectal cancer,” she says.
Goligher’s groundbreaking book
The event, called the John Goligher Visiting Fellow, is intended to attract international experts to share experiences in colorectal surgery. It is supported by a donation from Sir Berkeley Moynihan, a renowned British surgeonactive in the early 1900s.
Who was John Goligher, and why is his work significant? “He was a pioneer in colorectal cancer surgery in the UK. John Goligher is known for his surgical skill and his landmark reference book, Surgery of the Anus, Rectum, and Colon (originally published in 1961). It is still published in two large volumes and used by surgeons worldwide,” explains Eva Angenete.
Collaboration strengthens studies
Angenete hopes several collaborative projects with colleagues at the University of Leeds will get underway and that the John Goligher Colorectal Surgery Unit will also join some of the clinical studies being launched in Gothenburg.
“This could mean faster patient recruitment for the studies and greater generalizability, meaning that the research results could be applicable to a broader patient population,” she says.